Epstein Secrets

_R1_01138804 EFTA02295530 Investing in High Technology • Russian wealth needs investments in stable economies & access to centers of innovation (Silicon Valley) • European economies remain vulnerable • Investors need diversification Various economies Different industries Mix of risk levels • Demand for

s predecessor companies, culminating in his tenure as President of GSK's International Pharmaceuticals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and Vir

_APII AL LL, EFTA00506109 Investing in High Technology • Russian wealth needs investments in stable economies & access to centers of innovation (Silicon Valley) • European economies remain vulnerable • Investors need diversification • Various economies • Different industries • Mix of risk levels • Dema

s predecessor companies, culminating in his tenure as President of GSK's International Pharmaceuticals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and Vir

ECHNOLOGIES EFTA00506158 Investing in High Technology • Russian wealth needs investments in stable economies & access to centers of innovation (Silicon Valley) • European economies are threatened by upcoming currency crisis • Investors need diversification • Various economies • Different industries •

s predecessor companies, culminating in his tenure as President of GSK's International Pharmaceuticals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and Vir